AMKL
MCID: MGK001
MIFTS: 64

Megakaryocytic Leukemia (AMKL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Megakaryocytic Leukemia

MalaCards integrated aliases for Megakaryocytic Leukemia:

Name: Megakaryocytic Leukemia 38 12 15
Acute Megakaryoblastic Leukemia 12 76 53 59 6
Acute Megakaryocytic Leukemias 12 73
Acute Megakaryocytic Leukemia 53 59
Acute Myeloid Leukemia M7 53 59
Aml M7 53 59
Amkl 53 59
Acute Megakaryoblastic Leukaemia, Fab M7 12
Acute Megakaryoblastic Leukemia, Fab M7 12
Acute Myeloblastic Leukemia Type 7 53
Leukemia, Megakaryoblastic, Acute 44
Megakaryoblastic Leukemia, Acute 13
Megakaryoblastic Leukemia Acute 55
Leukemia, Myelocytic, Acute 73
Megakaryocytic Myelosis 12
Thrombocytic Leukaemia 12

Characteristics:

Orphanet epidemiological data:

59
acute megakaryoblastic leukemia
Inheritance: Not applicable; Age of onset: Childhood;

Classifications:



External Ids:

Disease Ontology 12 DOID:8761
ICD10 33 C94.2 C94.20
ICD9CM 35 207.2
MeSH 44 D007947
NCIt 50 C3170
SNOMED-CT 68 52220008 94149003
Orphanet 59 ORPHA518
ICD10 via Orphanet 34 C94.2
UMLS via Orphanet 74 C0023462

Summaries for Megakaryocytic Leukemia

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 518Disease definitionAcute megakaryoblastic leukemia (AMKL) is a form of acute myeloid leukemia (AML; see this term) that occurs predominantly in childhood and particularly in children with Down syndrome (DS-AMKL). Nonspecific symptoms may be irritability, weakness, and dizziness while specific symptoms include pallor, fever, mucocutaneous bleeding, hepatosplenomegaly, neurological manifestations and rarely lymphadenopathy. Acute panmyelosis with myelofibrosis (see this term)may also be associated with AMKL. In contrast to DS-AMKL (around 80 % survival), non-DS-AMKL is an AML subgroup associated with poor prognosis.Visit the Orphanet disease page for more resources.

MalaCards based summary : Megakaryocytic Leukemia, also known as acute megakaryoblastic leukemia, is related to leukemia and refractory anemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Megakaryocytic Leukemia is GATA1 (GATA Binding Protein 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased cell death HMECs cells and Reduced mammosphere formation

Disease Ontology : 12 A leukemia that derives from blood-forming tissue in which megakaryocytes proliferate in the bone marrow and circulate in the blood in large numbers.

Wikipedia : 76 Acute megakaryoblastic leukemia (AMKL) is life-threatening leukemia in which malignant megakaryoblasts... more...

Related Diseases for Megakaryocytic Leukemia

Diseases related to Megakaryocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Related Disease Score Top Affiliating Genes
1 leukemia 31.3 CSF2 JAK2 MRTFA RUNX1 TP53
2 refractory anemia 30.5 IL3 JAK2 RUNX1
3 acute erythroid leukemia 30.4 JAK2 TP53
4 myelofibrosis 30.3 GATA1 IL3 JAK2 THPO
5 polycythemia 29.9 IL3 JAK2 KITLG THPO
6 thrombocytopenia 29.9 GATA1 IL11 ITGA2B PF4 THPO
7 thrombocytosis 29.9 CSF2 IL11 IL3 JAK2 THPO
8 myeloid leukemia 29.8 CSF2 IL3 JAK2 RUNX1 TP53
9 acute leukemia 29.7 IL3 JAK2 MPO RUNX1
10 myelodysplastic syndrome 29.6 CSF2 GATA1 IL11 IL3 JAK2 KITLG
11 polycythemia vera 29.6 IL3 JAK2 JAK3 KITLG PF4 THPO
12 leukemia, chronic myeloid 29.2 CSF2 GATA1 IL3 JAK2 KITLG MPO
13 leukemia, acute myeloid 28.8 CSF2 GATA1 IL3 JAK2 KITLG MPO
14 essential thrombocythemia 28.6 GATA1 IL11 IL3 ITGA2B JAK2 MPO
15 acute megakaryoblastic leukemia in down syndrome 12.5
16 acute megakaryoblastic leukemia without down syndrome 12.3
17 myeloproliferative syndrome, transient 11.4
18 germ cells tumors 10.4
19 down syndrome 10.3
20 megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) 10.3 MRTFA RBM15
21 seborrheic infantile dermatitis 10.3 CSF2 IL3
22 chromosomal triplication 10.3
23 cyclic neutropenia 10.2 CSF2 IL3 KITLG
24 anemia of prematurity 10.2 CSF2 IL3 KITLG
25 retinitis pigmentosa and erythrocytic microcytosis 10.2 IL3 JAK2
26 trichosporonosis 10.2 CBS CSF2
27 platelet aggregation, spontaneous 10.2 PF4 VWF
28 chronic myelomonocytic leukemia 10.2 CSF2 JAK2 RUNX1
29 severe congenital neutropenia 10.1 CSF2 IL3 JAK2 KITLG
30 neuroblastoma 10.1
31 acute panmyelosis with myelofibrosis 10.1
32 leukocyte disease 10.1 CSF2 IL3 TP53
33 acquired von willebrand syndrome 10.1 JAK2 VWF
34 acquired thrombocytopenia 10.1 IL11 THPO
35 acute lymphocytic leukemia 10.1 CSF2 RUNX1 TP53
36 thrombocytopenia-absent radius syndrome 10.1 GATA1 JAK2 THPO
37 pancytopenia 10.1 CSF2 IL3 THPO
38 erythrocytosis, familial, 1 10.1 IL3 JAK2 THPO
39 thrombocytopenic purpura, autoimmune 10.0 IL11 ITGA2B THPO
40 primary thrombocytopenia 10.0 ITGA2B THPO VWF
41 autoimmune disease of blood 10.0 ITGA2B THPO VWF
42 exanthema subitum 10.0 ITGA2B KITLG THPO
43 acute basophilic leukemia 10.0 GATA1 MPO
44 purpura 10.0 ITGA2B THPO VWF
45 lymphoma, non-hodgkin, familial 10.0 CSF2 IL3 JAK2 TP53
46 juvenile myelomonocytic leukemia 10.0 CSF2 JAK2 JAK3 RUNX1
47 pulmonary hypertension 10.0
48 hematopoietic stem cell transplantation 10.0
49 sarcoma 10.0
50 myeloid sarcoma 10.0

Comorbidity relations with Megakaryocytic Leukemia via Phenotypic Disease Network (PDN):


Acquired Thrombocytopenia Deficiency Anemia
Neutropenia

Graphical network of the top 20 diseases related to Megakaryocytic Leukemia:



Diseases related to Megakaryocytic Leukemia

Symptoms & Phenotypes for Megakaryocytic Leukemia

UMLS symptoms related to Megakaryocytic Leukemia:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.43 CSF2 IL11 IL3 JAK2 PTEN TP53
2 Reduced mammosphere formation GR00396-S 9.28 CBS GATA1 IL6R ITGA2B JAK3 PTEN

MGI Mouse Phenotypes related to Megakaryocytic Leukemia:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 CSF2 GATA1 IL6R ITGA2B JAK2 JAK3
2 hematopoietic system MP:0005397 10.31 CSF2 GATA1 IL6R ITGA2B JAK2 JAK3
3 cardiovascular system MP:0005385 10.24 CSF2 GATA1 ITGA2B KITLG MPO MRTFA
4 homeostasis/metabolism MP:0005376 10.24 CSF2 GATA1 IL6R ITGA2B JAK2 KITLG
5 immune system MP:0005387 10.2 CSF2 GATA1 IL6R ITGA2B JAK2 JAK3
6 endocrine/exocrine gland MP:0005379 10.13 CSF2 IL6R JAK2 JAK3 KITLG MRTFA
7 embryo MP:0005380 10.11 CSF2 GATA1 ITGA2B JAK2 KITLG PTEN
8 integument MP:0010771 9.86 CSF2 GATA1 JAK2 KITLG MRTFA PTEN
9 mortality/aging MP:0010768 9.8 CSF2 GATA1 IL6R JAK2 JAK3 KITLG
10 liver/biliary system MP:0005370 9.7 GATA1 IL6R JAK2 KITLG PTEN RUNX1
11 neoplasm MP:0002006 9.23 CSF2 IL6R JAK2 KITLG PTEN RBM15

Drugs & Therapeutics for Megakaryocytic Leukemia

Drugs for Megakaryocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1 52-24-4 5453
4 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Antilymphocyte Serum Phase 4,Phase 2,Phase 1
10
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
11
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
12
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
13
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
14
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
15
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
16
Mesna Approved, Investigational Phase 3 3375-50-6 598
17
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
18
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
19
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
20
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123318-82-1 119182
21
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
22
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
23
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
24
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
26
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
27
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
28
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
29
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
30
Methotrexate Approved Phase 3,Phase 2,Phase 1 59-05-2, 1959-05-2 126941
31
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
32
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
33
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 320-67-2 9444
34
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
35
Carmustine Approved, Investigational Phase 3 154-93-8 2578
36
Hydroxyurea Approved Phase 3 127-07-1 3657
37
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
38
Midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
39
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
40
Cyproheptadine Approved Phase 3 129-03-3 2913
41
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
43
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
44 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
45 Vaccines Phase 3
46 Gemtuzumab Phase 2, Phase 3,Phase 3,Phase 1
47 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Analgesics Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
3 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
4 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
5 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
6 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
7 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
8 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
9 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
10 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
11 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
12 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
13 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
14 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
15 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
16 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
17 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
18 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
19 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
20 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
21 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
22 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
23 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
24 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
25 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
26 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
27 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
28 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
29 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
30 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
31 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
32 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
33 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
34 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
35 Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy Unknown status NCT00509093 Phase 2 imatinib mesylate
36 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
37 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
38 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
39 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
40 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
41 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
42 Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
43 Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
44 Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003396 Phase 2 cyclophosphamide;melphalan
45 Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate
46 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
47 Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer Completed NCT00003335 Phase 2 busulfan;cyclosporine;melphalan;methylprednisolone
48 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
49 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
50 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine

Search NIH Clinical Center for Megakaryocytic Leukemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Megakaryocytic Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, megakaryoblastic, acute

Genetic Tests for Megakaryocytic Leukemia

Anatomical Context for Megakaryocytic Leukemia

MalaCards organs/tissues related to Megakaryocytic Leukemia:

41
Myeloid, Bone, Bone Marrow, T Cells, Kidney, Lung, Monocytes

Publications for Megakaryocytic Leukemia

Articles related to Megakaryocytic Leukemia:

(show top 50) (show all 355)
# Title Authors Year
1
Clinical diagnosis of adult patients with acute megakaryocytic leukemia. ( 30546432 )
2018
2
Megakaryocytic leukemia 1 (MKL1) mediates high glucose induced epithelial-mesenchymal transition by activating LOX transcription. ( 30553442 )
2018
3
A case of KMT2A-SEPT9 fusion associated acute megakaryoblastic leukemia. ( 30455225 )
2018
4
Acute Megakaryoblastic Leukemia With Diffuse Periosteal Reaction of Bilateral Lower Extremities. ( 30303870 )
2018
5
Trisomy 3 as an acquired cytogenetic abnormality in primary acute megakaryoblastic leukemia. ( 30249908 )
2018
6
A pediatric case of acute megakaryocytic leukemia with double chimeric transcripts of CBFA2T3-GLIS2 and DHH-RHEBL1. ( 29043865 )
2018
7
Megakaryocytic Leukemia 1 (MKL1) Bridges Epigenetic Activation of NADPH Oxidase in Macrophages to Cardiac Ischemia-Reperfusion Injury. ( 30018168 )
2018
8
Thrombocytosis and central nervous system involvement in a case of canine acute megakaryoblastic leukemia. ( 30024652 )
2018
9
Acute Megakaryoblastic Leukemia Developing as Donor Cell Leukemia after Umbilical Cord Blood Transplantation. ( 29151503 )
2018
10
NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy. ( 29427526 )
2018
11
Cytoplasmic CD3 expression in infant acute megakaryoblastic leukemia: A new ambiguous lineage subtype? ( 29935384 )
2018
12
The Comparative Sensitivity of Immunohistochemical Markers of Megakaryocytic Differentiation in Acute Megakaryoblastic Leukemia. ( 30052718 )
2018
13
Down-syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome. ( 29217785 )
2017
14
Prognostic Impact of Specific Molecular Profiles in Pediatric Acute Megakaryoblastic Leukemia in Non-Down Syndrome. ( 28063190 )
2017
15
ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. ( 28292442 )
2017
16
Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. ( 29303660 )
2017
17
Smoldering Development of Acute Megakaryoblastic Leukemia with Clonal Evolution in an Infant without Down Syndrome. ( 29132167 )
2017
18
Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. ( 28112737 )
2017
19
New hPSC-based human models to study pediatric Acute Megakaryoblastic Leukemia harboring the fusion oncogene RBM15-MKL1. ( 28412998 )
2017
20
A Novel Variant t(1;22) Translocation - ins(22;1)(q13;p13p31) - in a Child with Acute Megakaryoblastic Leukemia. ( 28420865 )
2017
21
Treatment of critical hypercalcemia using pamidronate in acute megakaryoblastic leukemia in an 18-month-old girl. ( 28427853 )
2017
22
Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia. ( 28578457 )
2017
23
Pediatric Acute Megakaryoblastic Leukemia: Multitasking Fusion Proteins and Oncogenic Cooperations. ( 28867167 )
2017
24
Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR-ABL transcripts. ( 29089774 )
2017
25
ANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia. ( 29269781 )
2017
26
Alpha-Synuclein Expression in Acute Erythroleukaemia, Acute Megakaryoblastic Leukemia, and Normal Counterparts in Bone Marrow. ( 29760756 )
2017
27
Clinical Courses of Two Pediatric Patients with Acute Megakaryoblastic Leukemia Harboring the CBFA2T3-GLIS2 Fusion Gene. ( 27094503 )
2016
28
CCND1-BCL2 Gene Network: A direct target of Amifostine in human acute megakaryocytic leukemia cells. ( 27762064 )
2016
29
Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. ( 27244257 )
2016
30
Post-allogeneic stem cell transplant extramedullary relapse of acute megakaryoblastic leukemia initially detected by elevated WT1 mRNA levels in peripheral blood. ( 27941279 )
2016
31
Acute Megakaryoblastic Leukemia with Myelodysplasia-related Changes Associated with ATM Gene Deletion. ( 27301517 )
2016
32
Blockage of miR-92a-3p with locked nucleic acid induces apoptosis and prevents cell proliferation in human acute megakaryoblastic leukemia. ( 26658357 )
2016
33
Baicalein antagonizes acute megakaryoblastic leukemia in vitro and in vivo by inducing cell cycle arrest. ( 27042290 )
2016
34
A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia. ( 27148581 )
2016
35
Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. ( 25913479 )
2015
36
MiR-125b and miR-99a encoded on chromosome 21 co-regulate vincristine resistance in childhood acute megakaryoblastic leukemia. ( 25571789 )
2015
37
Megakaryocytic leukemia 1 directs a histone h3 lysine 4 methyltransferase complex to regulate hypoxic pulmonary hypertension. ( 25646298 )
2015
38
MN1-Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells. ( 26690545 )
2015
39
Acute megakaryocytic leukemia: What have we learned. ( 26228843 )
2015
40
Presentation of Acute Megakaryoblastic Leukemia Associated with a GATA-1 Mutation Mimicking the Eruption of Transient Myeloproliferative Disorder. ( 26205501 )
2015
41
Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children. ( 25266042 )
2015
42
Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype. ( 25361478 )
2015
43
Transient abnormal myelopoiesis/acute megakaryoblastic leukemia diagnosed in the placenta of a stillborn Down syndrome fetus with targeted next-generation sequencing. ( 25179734 )
2015
44
Very late relapse of Philadelphia chromosome positive acute megakaryoblastic leukemia. ( 25495169 )
2015
45
Constitutional chromosomal abnormality identified in a sibling donor after bone marrow stem cell transplantation in a pediatric patient with acute megakaryoblastic leukemia. ( 25553302 )
2015
46
Acute Megakaryoblastic Leukemia with t(1;22) Mimicking Neuroblastoma in an Infant. ( 25805677 )
2015
47
Clinical and hematological profile of acute megakaryoblastic leukemia: a 2 year study. ( 25825554 )
2015
48
Neonatal acute megakaryoblastic leukemia mimicking congenital neuroblastoma. ( 25838902 )
2015
49
A case of pentasomy 21 with two isochromosome 21s in acute megakaryoblastic leukemia associated with Down syndrome. ( 25932450 )
2015
50
An Unusual Case of Myeloperoxidase-Positive Acute Megakaryoblastic Leukemia. ( 26131422 )
2015

Variations for Megakaryocytic Leukemia

ClinVar genetic disease variations for Megakaryocytic Leukemia:

6 (show all 34)
# Gene Variation Type Significance SNP ID Assembly Location
1 GATA1 NM_002049.3(GATA1): c.154_173dup20 (p.Ala59Glnfs) duplication Pathogenic rs398124628 GRCh37 Chromosome X, 48649670: 48649689
2 GATA1 NM_002049.3(GATA1): c.154_173dup20 (p.Ala59Glnfs) duplication Pathogenic rs398124628 GRCh38 Chromosome X, 48791263: 48791282
3 JAK3 NM_000215.3(JAK3): c.2164G> A (p.Val722Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs3213409 GRCh37 Chromosome 19, 17945696: 17945696
4 JAK3 NM_000215.3(JAK3): c.2164G> A (p.Val722Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs3213409 GRCh38 Chromosome 19, 17834887: 17834887
5 JAK3 NM_000215.3(JAK3): c.394C> A (p.Pro132Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs3212723 GRCh37 Chromosome 19, 17954215: 17954215
6 JAK3 NM_000215.3(JAK3): c.394C> A (p.Pro132Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs3212723 GRCh38 Chromosome 19, 17843406: 17843406
7 PTEN NM_000314.6(PTEN): c.406T> C (p.Cys136Arg) single nucleotide variant Pathogenic rs786201044 GRCh37 Chromosome 10, 89692922: 89692922
8 PTEN NM_000314.6(PTEN): c.406T> C (p.Cys136Arg) single nucleotide variant Pathogenic rs786201044 GRCh38 Chromosome 10, 87933165: 87933165
9 SLC9A2 NM_003048.5(SLC9A2): c.2168delC (p.Gln725Serfs) deletion Uncertain significance rs864309496 GRCh37 Chromosome 2, 103324677: 103324677
10 SLC9A2 NM_003048.5(SLC9A2): c.2168delC (p.Gln725Serfs) deletion Uncertain significance rs864309496 GRCh38 Chromosome 2, 102708218: 102708218
11 ACPP NM_001134194.1(ACPP): c.848_850delTCA (p.Ile284del) deletion Uncertain significance rs864309497 GRCh38 Chromosome 3, 132349986: 132349988
12 ACPP NM_001134194.1(ACPP): c.848_850delTCA (p.Ile284del) deletion Uncertain significance rs864309497 GRCh37 Chromosome 3, 132068830: 132068832
13 MDGA1 NM_153487.3(MDGA1): c.2674T> G (p.Phe892Val) single nucleotide variant Uncertain significance rs864309493 GRCh38 Chromosome 6, 37638307: 37638307
14 MDGA1 NM_153487.3(MDGA1): c.2674T> G (p.Phe892Val) single nucleotide variant Uncertain significance rs864309493 GRCh37 Chromosome 6, 37606083: 37606083
15 PCF11 NM_015885.3(PCF11): c.3223delT (p.Phe1075Leufs) deletion Uncertain significance rs864309498 GRCh37 Chromosome 11, 82880600: 82880600
16 PCF11 NM_015885.3(PCF11): c.3223delT (p.Phe1075Leufs) deletion Uncertain significance rs864309498 GRCh38 Chromosome 11, 83169558: 83169558
17 CORO7 NM_024535.4(CORO7): c.2772+50C> T single nucleotide variant Uncertain significance rs864309494 GRCh38 Chromosome 16, 4355236: 4355236
18 CORO7 NM_024535.4(CORO7): c.2772+50C> T single nucleotide variant Uncertain significance rs864309494 GRCh37 Chromosome 16, 4405237: 4405237
19 TP53 NM_000546.5(TP53): c.636delT (p.Arg213Aspfs) deletion Pathogenic rs864309495 GRCh38 Chromosome 17, 7674895: 7674895
20 TP53 NM_000546.5(TP53): c.636delT (p.Arg213Aspfs) deletion Pathogenic rs864309495 GRCh37 Chromosome 17, 7578213: 7578213
21 RASAL3 NM_022904.2(RASAL3): c.-5C> G single nucleotide variant Uncertain significance rs76267899 GRCh38 Chromosome 19, 15464363: 15464363
22 RASAL3 NM_022904.2(RASAL3): c.-5C> G single nucleotide variant Uncertain significance rs76267899 GRCh37 Chromosome 19, 15575174: 15575174
23 MT-ND6 NC_012920.1: m.14372C> A single nucleotide variant Uncertain significance rs386829210 GRCh37 Chromosome MT, 14372: 14372
24 MT-ND6 NC_012920.1: m.14372C> A single nucleotide variant Uncertain significance rs386829210 GRCh38 Chromosome MT, 14372: 14372
25 JAK3 NM_000215.3(JAK3): c.1503G> C (p.Gln501His) single nucleotide variant Likely pathogenic rs201283129 GRCh37 Chromosome 19, 17949138: 17949138
26 JAK3 NM_000215.3(JAK3): c.1503G> C (p.Gln501His) single nucleotide variant Likely pathogenic rs201283129 GRCh38 Chromosome 19, 17838329: 17838329
27 JAK3 NM_000215.3(JAK3): c.1715C> T (p.Ala572Val) single nucleotide variant Likely pathogenic rs121913504 GRCh37 Chromosome 19, 17948009: 17948009
28 JAK3 NM_000215.3(JAK3): c.1715C> T (p.Ala572Val) single nucleotide variant Likely pathogenic rs121913504 GRCh38 Chromosome 19, 17837200: 17837200
29 JAK3 NM_000215.3(JAK3): c.1970G> A (p.Arg657Gln) single nucleotide variant Likely pathogenic rs758959409 GRCh37 Chromosome 19, 17945969: 17945969
30 JAK3 NM_000215.3(JAK3): c.1970G> A (p.Arg657Gln) single nucleotide variant Likely pathogenic rs758959409 GRCh38 Chromosome 19, 17835160: 17835160
31 JAK3 NM_000215.3(JAK3): c.1503G> T (p.Gln501His) single nucleotide variant Likely pathogenic rs201283129 GRCh37 Chromosome 19, 17949138: 17949138
32 JAK3 NM_000215.3(JAK3): c.1503G> T (p.Gln501His) single nucleotide variant Likely pathogenic rs201283129 GRCh38 Chromosome 19, 17838329: 17838329
33 JAK3 NM_000215.3(JAK3): c.260T> C (p.Ile87Thr) single nucleotide variant Likely pathogenic rs1057519770 GRCh37 Chromosome 19, 17954634: 17954634
34 JAK3 NM_000215.3(JAK3): c.260T> C (p.Ile87Thr) single nucleotide variant Likely pathogenic rs1057519770 GRCh38 Chromosome 19, 17843825: 17843825

Copy number variations for Megakaryocytic Leukemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 158678 21 35304204 35704075 Loss RUNX1 Acute megakaryoblastic leukaemia

Expression for Megakaryocytic Leukemia

Search GEO for disease gene expression data for Megakaryocytic Leukemia.

Pathways for Megakaryocytic Leukemia

Pathways related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 CSF2 IL3 IL6R ITGA2B JAK2 JAK3
2
Show member pathways
14.02 CSF2 IL11 IL3 IL6R ITGA2B JAK2
3
Show member pathways
13.79 CSF2 IL11 IL3 IL6R ITGA2B JAK2
4
Show member pathways
13.64 CSF2 IL11 IL3 IL6R JAK2 JAK3
5
Show member pathways
13.51 IL11 IL3 IL6R ITGA2B JAK2 JAK3
6
Show member pathways
13.3 CSF2 IL11 IL3 IL6R ITGA2B JAK2
7
Show member pathways
13.26 CSF2 IL11 IL3 IL6R JAK2 KITLG
8
Show member pathways
13.25 CSF2 GATA1 IL3 ITGA2B JAK2 JAK3
9
Show member pathways
13.18 CSF2 IL11 IL3 IL6R ITGA2B JAK2
10
Show member pathways
13.04 IL3 ITGA2B KITLG PTEN THPO TP53
11
Show member pathways
12.93 IL3 IL6R ITGA2B JAK2 JAK3 KITLG
12
Show member pathways
12.85 IL11 ITGA2B JAK2 JAK3 PTEN SRF
13
Show member pathways
12.85 CSF2 IL3 MPO PTEN RUNX1 TP53
14
Show member pathways
12.74 IL6R JAK2 JAK3 PTEN TP53
15 12.74 IL3 IL6R ITGA2B JAK2 JAK3 KITLG
16 12.44 GATA1 IL3 JAK2 JAK3 KITLG MPO
17 12.39 CSF2 JAK3 SRF TP53
18
Show member pathways
12.37 CSF2 IL11 IL3 IL6R JAK2 JAK3
19
Show member pathways
12.36 JAK2 JAK3 PTEN TP53
20 12.23 CSF2 IL3 MPO RUNX1 TP53
21
Show member pathways
12.17 IL6R ITGA2B PTEN TP53
22
Show member pathways
12.16 IL3 JAK2 KITLG PTEN
23
Show member pathways
12.13 CSF2 IL3 JAK2 JAK3
24 12.11 IL6R ITGA2B PTEN TP53
25
Show member pathways
12.05 IL11 IL3 IL6R JAK2 KITLG THPO
26 12.01 GATA1 IL11 IL3 KITLG RUNX1 THPO
27 11.97 IL6R JAK2 JAK3 TP53
28 11.91 IL3 IL6R PTEN TP53
29
Show member pathways
11.86 ITGA2B THPO VWF
30 11.86 IL3 IL6R JAK2 JAK3
31
Show member pathways
11.85 CSF2 IL6R JAK2 JAK3
32 11.83 ITGA2B PTEN TP53
33 11.76 CSF2 IL11 IL3 ITGA2B KITLG MPO
34 11.74 GATA1 KITLG MPO
35 11.68 IL3 ITGA2B KITLG THPO
36
Show member pathways
11.61 IL11 IL6R JAK2
37 11.51 IL11 IL3 IL6R KITLG
38 11.43 MRTFA PTEN SRF
39 11.37 IL11 ITGA2B JAK2 JAK3 SRF
40 11.24 CSF2 IL11 IL3
41 11.19 CSF2 IL11 IL3 PF4
42 11.15 CSF2 IL11 IL3 IL6R ITGA2B KITLG
43 11.11 CSF2 GATA1 IL3 ITGA2B KITLG RUNX1
44 10.99 CSF2 IL11 IL3 ITGA2B KITLG PF4

GO Terms for Megakaryocytic Leukemia

Cellular components related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 CSF2 IL11 IL3 IL6R KITLG MPO

Biological processes related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.97 GATA1 JAK2 PTEN SRF TP53
2 regulation of signaling receptor activity GO:0010469 9.87 CSF2 IL11 IL3 IL6R KITLG PF4
3 positive regulation of cell proliferation GO:0008284 9.86 CSF2 IL11 IL3 IL6R JAK2 KITLG
4 peptidyl-tyrosine phosphorylation GO:0018108 9.85 CSF2 IL3 JAK2 JAK3
5 MAPK cascade GO:0000165 9.83 CSF2 IL3 JAK2 JAK3 KITLG
6 erythrocyte differentiation GO:0030218 9.69 GATA1 JAK2 JAK3
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 CSF2 IL3 IL6R JAK2
8 long-term synaptic depression GO:0060292 9.65 PTEN SRF
9 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.65 CSF2 GATA1 PF4
10 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.64 CSF2 PF4
11 interleukin-6-mediated signaling pathway GO:0070102 9.63 IL6R JAK2
12 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.63 JAK2 JAK3
13 positive regulation of leukocyte migration GO:0002687 9.62 ITGA2B KITLG
14 dendritic cell differentiation GO:0097028 9.62 CSF2 GATA1
15 regulation of JAK-STAT cascade GO:0046425 9.61 JAK2 JAK3
16 regulation of myeloid cell differentiation GO:0045637 9.61 CSF2 RUNX1
17 tyrosine phosphorylation of STAT protein GO:0007260 9.6 JAK2 JAK3
18 enzyme linked receptor protein signaling pathway GO:0007167 9.59 JAK2 JAK3
19 regulation of cytokine-mediated signaling pathway GO:0001959 9.58 IL3 RUNX1
20 embryonic hemopoiesis GO:0035162 9.58 GATA1 IL3 KITLG
21 megakaryocyte differentiation GO:0030219 9.56 GATA1 IL11
22 cytokine-mediated signaling pathway GO:0019221 9.56 CSF2 IL11 IL3 IL6R JAK2 JAK3
23 regulation of megakaryocyte differentiation GO:0045652 9.55 GATA1 ITGA2B PF4 RBM15 RUNX1
24 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.54 KITLG THPO
25 positive regulation of transcription via serum response element binding GO:0010735 9.52 MRTFA SRF
26 thrombopoietin-mediated signaling pathway GO:0038163 9.49 RBM15 THPO
27 negative regulation of cytolysis GO:0045918 9.46 CSF2 PF4
28 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.17 GATA1 IL11 IL3 IL6R JAK2 KITLG
29 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 GATA1 IL11 MRTFA PF4 RUNX1 SRF
30 negative regulation of apoptotic process GO:0043066 10.04 GATA1 KITLG MPO PTEN TP53

Molecular functions related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.67 GATA1 RUNX1 SRF TP53
2 protein tyrosine kinase activity GO:0004713 9.56 CSF2 IL3 JAK2 JAK3
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.55 CSF2 IL3 JAK2 JAK3 KITLG
4 cytokine activity GO:0005125 9.43 CSF2 IL11 IL3 KITLG PF4 THPO
5 interleukin-12 receptor binding GO:0005143 9.32 IL6R JAK2
6 growth factor activity GO:0008083 9.1 CSF2 IL11 IL3 IL6R KITLG THPO
7 protein binding GO:0005515 10.33 CBS CSF2 GATA1 IL11 IL6R ITGA2B

Sources for Megakaryocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....